Scientists in Australia begin preclinical study that may help halt MS progression
Researchers from Monash University in Australia are set to conduct a large study into a drug that may one day help halt the progression of multiple sclerosis (MS)...Read more - http://www.ms-uk.org/scientists-austral ... rogression
Scientists in Australia begin preclinical study...
Scientists in Australia begin preclinical study...
MS-UK - http://www.ms-uk.org/
Re: Scientists in Australia begin preclinical study...
The compound beind studied, 3,5-diiodothyropropionic acid, is a thyroid hormone analog. I wasn't able to find any published studies of its use in MS, but it has been studied in congestive heart failure (CHF) patients.MSUK wrote:Scientists in Australia begin preclinical study that may help halt MS progression
Researchers from Monash University in Australia are set to conduct a large study into a drug that may one day help halt the progression of multiple sclerosis (MS)...Read more - http://www.ms-uk.org/scientists-austral ... rogression
https://www.ncbi.nlm.nih.gov/pubmed?ter ... ailsSearch
Re: Scientists in Australia begin preclinical study...
Hi,
Might not be as easy as it sounds. https://academic.oup.com/jcem/article/95/3/1349/2597364
Regards,
Might not be as easy as it sounds. https://academic.oup.com/jcem/article/95/3/1349/2597364
Regards,
Re: Scientists in Australia begin preclinical study...
Scott1 wrote:Hi,
Might not be as easy as it sounds. https://academic.oup.com/jcem/article/95/3/1349/2597364
In conclusion, this phase II trial in patients treated with the thyroid hormone analog DITPA has shown that the agent has significant LDL cholesterol-lowering properties and that it can induce significant weight loss. However, DITPA’s actual clinical safety and efficacy would have to be demonstrated in a more definitive trial using a lower drug dosage that might be better tolerated. Whether its profile of adverse effects, which led to a high dropout rate and included apparently unfavorable effects on markers of bone metabolism, would justify such further investigation is arguable. However, this demonstration of potentially beneficial actions of a thyromimetic agent suggests the potential value of this drug class in patients with dyslipidemia and obesity.
So, why are they testing DITPA in MSIn December 2008, Titan Pharmaceutical discontinued its development of DITPA...
-
- Similar Topics
- Replies
- Views
- Last post